Tetracontanoic acid | 80440-54-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Tetracontanoic acid
• CAS: 80440-54-6
• 化学式: C₄₀H₈₀O₂
• 分子量: 593.1
• InChiKey: CWXZMNMLGZGDSW-UHFFFAOYSA-N

物化性质

• 沸点：
  557.59°C (rough estimate)
• 密度：
  0.8685 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  19.4
• 重原子数：
  42
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES<br/>[FR] ANTICORPS ANTI-TN-MUC1 HUMANISÉS ET LEURS CONJUGUÉS
  申请人：CANCER REC TECH LTD

  公开号：WO2015159076A1

  公开（公告）日：2015-10-22

  Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.

  人性化抗Tn-MUC1抗体及其结合物。描述了包含吡咯苯并二氮杂环己烷（PBDs）的结合物，其具有作为连接物的不稳定保护基团。
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT SITE-SPÉCIFIQUES
  申请人：VAN BERKEL PATRICIUS HENDRIKUS CORNELIS

  公开号：WO2016166299A1

  公开（公告）日：2016-10-20

  Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.

  特定于位点的抗体药物偶联物被描述，特别是包括结合PSMA的抗体的偶联物，其包括通过将链间半胱氨酸残基替换为非半胱氨酸和具有易裂解保护基的吡咯并苯二氮䓬啉（PBDs）的氨基酸的偶联物。偶联位置以及抗体部分的修饰，可以提高ADC的安全性和有效性。
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT SPÉCIFIQUES À UN SITE
  申请人：VAN BERKEL PATRICIUS HENDRIKUS CORNELIS

  公开号：WO2016166341A1

  公开（公告）日：2016-10-20

  Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds CD25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

  描述了特定于位点的抗体药物共轭物，特别是包括一种抗体的共轭物，该抗体结合CD25并包括通过氨基酸替换使一个链间半胱氨酸残基成为非半胱氨酸的氨基酸，以及具有以连接物形式的易降解保护基团的吡咯苯并二氮杂环己烯酮（PBDs）。结合位点以及抗体部分的修饰，可提高ADC的安全性和有效性。
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS SPÉCIFIQUE À UN SITE-MÉDICAMENT
  申请人：VAN BERKEL PATRICIUS HENDRIKUS CORNELIS

  公开号：WO2016166305A1

  公开（公告）日：2016-10-20

  Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds MUC1 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

  特定于部位的抗体药物偶联物被描述，特别是包含一种抗体的偶联物，该抗体结合MUC1并且包括通过非半胱氨酸替换间链半胱氨酸残基的氨基酸，以及具有以连接物形式的易降解保护基的吡咯苯二氮卓啉（PBDs）。偶联的部位以及抗体部分的修饰，可以提高ADC的安全性和有效性。
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-ANTICORPS SPÉCIFIQUES D'UN SITE
  申请人：VAN BERKEL PATRICIUS HENDRIKUS CORNELIS

  公开号：WO2016166298A1

  公开（公告）日：2016-10-20

  Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds CD19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.

  描述了特定于位点的抗体药物偶联物，特别是包括结合CD19的抗体的偶联物，该抗体包含通过非半胱氨酸替换间链半胱氨酸残基的氨基酸，以及具有以连接物形式的易降解保护基团的吡咯苯并二氮䓬（PBDs）。偶联的位点以及对抗体部分的修饰，可以提高ADC的安全性和有效性。